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e.2012.04Abstract Background: ICSI/ET in endometriosis patients has poor outcome by traditional proto-
cols. The key enzyme in the biosynthesis of estradiol, aromatase, has been demonstrated within
endometriosis. Combined administration of aromatase inhibitor and GnRH-agonist may efﬁciently
suppress estrogen biosynthesis through a combined pituitary, ovarian and local factors in the
implants.
Objective: Evaluate the effect of using letrozole in improvement of the results of ICSI/ET in endo-
metriosis women with long agonist protocol.
Patients: Sixty infertile women with minimal and mild endometriosis according to the revised
American Fertility Society classiﬁcation were scheduled for ICSI/ET.
Methods: Women were randomized into two groups. Group 1: using the traditional luteal long
agonist protocol using triptorelin 0.1 and Group 2: using letrozole 5 mg/day started 5 days afteric sperm injection and embryo
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304 M.S. Abd Rabbo et al.the start of GnRH agonist for 5 days. All patients were monitored with day 6 serum estradiol level
and estradiol at day of HCG. The number of days of stimulation, number of retrieved oocytes,
number of MII oocytes, cleavage rate, and pregnancy rate were studied in both groups.
Results: Days of stimulation were signiﬁcantly higher in the treated group (p= 0.019). Oocytes
number was not affected (10.57 ± 6.14) and (11.21 ± 6.41) (p= 0.516) in groups 1 and 2 respec-
tively also, the number of embryos was not affected (p= 0.955). Nine (32.1%) pregnant cases of 28
were in the ﬁrst group while 8 from 27 in the second group (29.6%).
Conclusion: Letrozole signiﬁcantly affected days of stimulation of ICSI cycle in endometriosis
patients without affecting pregnancy rate.
ª 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Endometriosis is an estrogen-dependent disorder deﬁned as the
presence of endometrial tissue outside of the uterine cavity.1
The increased incidence of infertility with endometriosis
may reﬂect a higher incidence of abnormal oocytes, defective
embryos or failed implantation. Patients with moderate or se-
vere endometriosis may have anatomic distortion of the fallo-
pian tubes and ovaries.2,3
Several studies have compared the success rates of IVF inwo-
menwith endometriosis withwomenwho have other indications
for IVF. Results suggested that fertilization rates were reduced
in women with endometriosis compared with those with tubal
or unexplained infertility.4 Others indicate lower pregnancy
and implantation rates in women with endometriosis.5,6
Prospective randomized trials have suggested that laparo-
scopic surgery improves fertility in mild/moderate endometri-
osis.7 Based on these studies surgical treatment of minimal to
mild endometriosis seems to offer a small but signiﬁcant ben-
eﬁt with regard to fertility outcome. Furthermore, the surgical
removal of peritoneal endometriosis may also be important to
prevent progression of endometriosis in some patients. How-
ever, care is needed to prevent adhesion formation that could
result as a consequence of over-enthusiastic excision of mini-
mal to mild endometriosis. After laparoscopic resection and
ablation of stages I–II endometriosis, monthly fecundity rate
in a randomized control trial was 4.7%, as compared with
2.4% for women who underwent only a diagnostic procedure.8
However, in some cases of minimal and mild endometriosis
non-visualized endometriotic spots either on the peritoneal
surface or deep implantation were identiﬁed on visually nor-
mal peritoneum.9
In a meta-analysis of three large studies it was found that
prolonged pretreatment with gonadotropin-releasing hormone
analogue before IVF has been reported to improve clinical
pregnancy rates in infertile women with endometriosis. The
administration of GnRH agonists for a period of 3–6 months
prior to IVF or ICSI in women with endometriosis increases
the odds of clinical pregnancy by fourfold.10
Another study, conﬁrmed that GnRH-a does not generally
improve results of ART. In mild endometriosis after
4 months of GnRH-a therapy, the pregnancy rates per em-
bryo transfer were not higher than those obtained with con-
ventional GnRH-a therapy in the long protocol before IVF–
ET.11 Also, in a randomized trial it was found that in pa-
tients with stage I or II endometriosis, there was no signiﬁ-cant difference between long and ultra long protocol with
respect to clinical pregnancy rate per cycle, also it is not suit-
able for poor responders plus the cost and the duration of
therapy.12 The recent evidence showed that suppression of
ovarian function to improve fertility in minimal and mild
endometriosis is not effective and should not be offered for
this indication alone.13
Studies have shown an increase in aromatase enzyme
expression and high levels of the enzyme itself in endometriotic
tissue. Small studies using the aromatase inhibitor anastrozole
have demonstrated a marked reduction in size of endometriot-
ic implants as well as a reduction or disappearance in pelvic
pain. Furthermore, the aromatase inhibitors not only block
aromatase activity within the ovary but also act directly on
the aromatase enzyme found in the endometriotic tissue, low-
ering both estrogen levels and PG E production. These two ac-
tions may potentially give it an advantage over the medical
treatments available.14,152. Aim of the work
The aim of this study is to evaluate the effect of using letrozole
(aromatase inhibitor) to improve the success of ICSI/ET in
women with minimal to mild endometriosis using the long
protocol.
2.1. Patients
All the women included in the study were recruited from infer-
tility clinic at the Elshatby Maternity University Hospital.
Sixty cases of minimal to mild endometriosis infertile wo-
men were scheduled for ICSI.
2.2. Inclusion criteria includes
I. Age less than 35 years.
II. Basal serum FSH less than 10 IU.
III. Minimal to mild endometriosis as diagnosed by laparos-
copy and lesions classiﬁed according to the revised
American Society for Reproductive Medicine scoring.2.3. Exclusion criteria include
I. Moderate or severe endometriosis according to the
revised American Society for Reproductive Medicine
scoring.
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III. Previous ovarian surgery.
3. Methods
All the women in the study started the luteal long agonist pro-
tocol at day 21 (midluteal) and the informed consent was taken
from the patients before the beginning of the study.
All the women were subjected to a peritoneal biopsy from
the suspected lesions during diagnostic laparoscopy. Histolog-
ical examination of the excised tissue was systematically car-
ried out after hematoxylin–eosin staining, and the nature of
the lesions was histologically conﬁrmed in all cases (presence
of glands and stroma). Then the patients were randomized into
two groups.
3.1. Group A 30 patients
All the women continued the long agonist protocol starting
GnRH agonist triptorelin (Decapeptyl) at midluteal phase
and starting stimulation using combined human menopausal
gonadotrophin and puriﬁed FSH after complete suppression
(300 IU).3.2. Group B 30 patients
The patients continued the long protocol and started the aro-
matase inhibitor (letrozole) 5 days after the start of the agonist
for 10 days of 5 mg/day as was done in a pilot study.
In both groups suppression was veriﬁed by: serum estra-
diol level less than 50 pg/ml, thin endometrium and no ovar-
ian activity. Both groups were followed up by follicularFigure 1 Flow chart oscanning and serial serum estradiol level till the criteria of
HCG fulﬁlled.
3.3. Criteria of HCG administration
 Most of the follicles were 18–20 mm.
 Serum estradiol level was 150–200 pg/ml for each follicle
>15 mm in diameter.
 Endometrial thickness was >9 mm.
Women were given 10,000 IU of HCG (Pregnyl, Organon,
Egypt).
Transvaginal guided oocyte retrieval was done 36 h after
HCG administration. Semen was prepared using the double
wash and swim up technique.
After oocyte preparation metaphase II oocytes were in-
jected. Fertilization was checked after 16–18 h and embryo
transfer after 48 h.
3.4. Main outcomes
Day 6 serum estradiol level, ﬁnal serum estradiol, endometrial
thickness and pattern, number of retrieved oocytes, number of
MII oocytes, fertilization rate, cleavage rate, and number of
class A embryos.
3.5. Secondary outcome
Pregnancy rate per embryo transfer was calculated.
4. Statistical analysis
Data were fed to the computer using the Predictive Analytics
Software (PASW Statistics 18).f the study design.
Table 1 Comparison between the two studied groups
according to days of stimulation.
Cases Control p value
(n= 27) (n= 28)
Days of stimulation
Range 11.0–16.0 10.0–16.0 0.019*
Mean ± SD 13.04 ± 1.53 12.07 ± 1.60
Median 13.0 12.0
p1: p value for Mann–Whitney test.
* Statistically signiﬁcant at p 6 0.05.
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and maximum as well as mean and standard deviation.
The distributions of quantitative variables were tested for
normality using Kolmogorov–Smirnov test, and Shapiro–Wilk
test. D’Agstino test was used if there was a conﬂict between
the two previous tests. If it reveals normal data distribution,
parametric tests were applied. If the data were abnormally dis-
tributed, non-parametric tests were used.
For abnormally distributed data, Mann–Whitney Test (for
data distribution that was signiﬁcantly deviated from normal)
was used to analyze two independent populations. Correla-
tions between two quantitative variables were assessed using
Spearman coefﬁcient.
Signiﬁcance test results are quoted as two-tailed probabili-
ties. Signiﬁcance of the obtained results was judged at the 5%
level.5. Results
Sixty women were included in the study population. They were
randomized into two groups. As shown in Fig. 1.
comparing the two studied groups, as regards the demo-
graphic data, it was found that there was no difference between
both groups as regards age and years of infertility.
It was found that the mean age in the treated group
was 29.07 ± 5.09 and 28.43 ± 5.08 in the control group
(p= 0.646).
Comparing both groups as regards days of stimulation it
was found that there was a signiﬁcant difference between the
days of stimulation between both groups (p, 0.019). In the
study group it was 13.04 ± 1.53 and 12.07 ± 1.60 in the con-
trol group (Table 1).
As regards the number of oocytes after ovum pick up, it
was found that there was no signiﬁcant difference between
the numbers of oocytes in both groups (11.21 ± 6.41) and
(10.57 ± 6.14) in study and control group respectively. Also
there was no signiﬁcant difference in the percentage of mature
oocytes in both groups (78.05 ± 16.93) and (78.98 ± 23.14)
(p, 0.516).
As regards the number of embryos, there was no signiﬁcant
difference between both groups (4.85 ± 3.29) and (4.0 ± 2.52)
in study and control group respectively.
Pregnancy rate was a secondary outcome measure in this
study and it did not show any signiﬁcant difference between
the two studied groups. It was 29.6% and 32.1% in the letroz-
ole treated group versus control group (p, 0.631).6. Discussion
Endometriosis is associated with reduced response after ICSI/
ET.16 In a meta-analysis of 22 published studies the conclusion
was that women with endometriosis have a reduced pregnancy
rate (21% for stages I–II and 14% for stages III–IV) compared
with that in women with tubal infertility. In addition, other
indicators, such as circulating estradiol levels, numbers of re-
trieved oocytes, and decreased fertilization and implantation
rates, have shown similar results.6
In the two meta-analysis of Sallam et al.10 it was concluded
that the administration of GnRH agonists for a period of 3–
6 months prior to IVF or ICSI in women with endometriosis
increases the odds of clinical pregnancy. But prolonged sup-
pression has high expenses and adverse effects of prolonged
pituitary down regulation.17
Till now there is no satisfactory stimulation protocol for
cases of endometriosis as regards cost and for improving re-
sults of IVF.
This study used an aromatase inhibitor during the phase of
down regulation before ICSI. This hypothesis is justiﬁed by the
intracrine production of estrogen by the implants which is
dependent not only on FSH but also locally regulated by
PGE2 which at the same time is dependent on estrogen pro-
duced by the implants. So, the pituitary down regulation by
GnRH agonist does not lead to complete suppression of the
implants.
As regards days of stimulation, compared to the classical
long agonist protocol, letrozole increased stimulation days sig-
niﬁcantly (p, 0.019). This may be due to high expression of
P450 aromatase in endometriosis that is suppressed by
letrozole.
As regards the serum level of day 6 stimulation and ﬁnal E2
there was no signiﬁcant difference between the studied groups.
The percent of class A embryos was the same in both the study
and the control group. This is due to the short term effect of
letrozole so, less harmful effects on endometrium and em-
bryos. These results are not different from what was found
by Shahine et al. 2009 that the surgical treatment of endome-
triosis did not alter embryo quality.18
As regards pregnancy rate, there was no signiﬁcant differ-
ence between the studied groups. This may be due to the small
number of each group. A big number may be needed to show
the effect. The dose of letrozole may be small for the expected
effect. Also, the effect of letrozole on endometrial receptivity
and implantation is a big question still not answered. But still
our results as regards pregnancy rate were comparable to preg-
nancy rate in the literature.6,19
Only one pilot study in 2009 had shown a new a protocol
for the preparation of endometriosis patients for ICSI similar
to ours but in cases of endometriomas. In the IVF/ICSI cycle,
ﬁve (25%) had a clinical pregnancy, and three (15%) delivered
healthy children (two singletons and one twin).19 This preg-
nancy rate is comparable to our study which was 29.5–32.1%.7. Conclusion
Letrozole has an effect on the duration of stimulation of ICSI
cycle in endometriosis patients without affecting pregnancy
rate.
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